Should I buy or sell Aura Biosciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aura Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AURA shares. View AURA analyst ratings or view top-rated stocks .

What is Aura Biosciences' stock price target for 2024?

3 brokerages have issued twelve-month price targets for Aura Biosciences' shares. Their AURA share price targets range from $19.00 to $23.00. On average, they expect the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 197.0% from the stock's current price. View analysts price targets for AURA or view top-rated stocks among Wall Street analysts .

How have AURA shares performed in 2024?

Aura Biosciences' stock was trading at $8.86 at the beginning of 2024. Since then, AURA stock has decreased by 20.2% and is now trading at $7.07. View the best growth stocks for 2024 here .

Are investors shorting Aura Biosciences?

Aura Biosciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,450,000 shares, an increase of 9.4% from the March 15th total of 2,240,000 shares. Based on an average daily trading volume, of 179,700 shares, the short-interest ratio is presently 13.6 days. Currently, 6.2% of the company's stock are sold short. View Aura Biosciences' Short Interest .

When is Aura Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our AURA earnings forecast .

How were Aura Biosciences' earnings last quarter?

Aura Biosciences, Inc. (NASDAQ:AURA) announced its quarterly earnings results on Wednesday, March, 15th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.06.

What ETFs hold Aura Biosciences' stock?

ETFs with the largest weight of Aura Biosciences (NASDAQ:AURA) stock in their portfolio include Loncar China Biopharma ETF (CHNA) and Range Cancer Therapeutics ETF (CNCR) . AltShares Event-Driven ET (EVNT) .

When did Aura Biosciences IPO?

Aura Biosciences (AURA) raised $81 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 5,400,000 shares at $14.00-$16.00 per share.

How do I buy shares of Aura Biosciences?

Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AURA

Aura Biosciences (AURA) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free AURA Stock Alerts

$7.11

+0.05 (+0.71%)

(As of 01:51 PM ET)

Compare

Today's Range: $7.03
▼
$7.19
50-Day Range: $7.03
▼
$9.24
52-Week Range: $5.99
▼
$13.50

Volume: 54,287 shs
Average Volume: 170,927 shs
Market Capitalization: $351.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.00

Get Aura Biosciences alerts:

Aura Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 197.0% Upside
$21.00 Price Target
Short Interest: Bearish
6.17% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.28
Based on 2 Articles This Week
Insider Trading: Selling Shares
$171,610 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.02) to ($1.92) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.87 out of 5 stars

Medical Sector

599th out of 918 stocks

Biological Products, Except Diagnostic Industry

97th out of 151 stocks

3.5

Analyst's Opinion

Consensus Rating
Aura Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Aura Biosciences has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
6.17% of the float of Aura Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Aura Biosciences has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Aura Biosciences has recently increased by 9.38%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Aura Biosciences does not currently pay a dividend.
Dividend Growth
Aura Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AURA.

3.5

News and Social Media Coverage

News Sentiment
Aura Biosciences has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Aura Biosciences this week, compared to 1 article on an average week.
Search Interest
6 people have searched for AURA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Aura Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aura Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $171,610.00 in company stock.
Percentage Held by Insiders
Only 5.90% of the stock of Aura Biosciences is held by insiders.
Percentage Held by Institutions
96.75% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Aura Biosciences are expected to grow in the coming year, from ($2.02) to ($1.92) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aura Biosciences is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aura Biosciences is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aura Biosciences has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad The Bull Report

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

Click here to see why this small company is trusted by the Mayo Clinic

About Aura Biosciences Stock (NASDAQ:AURA)

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

AURA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AURA Stock News Headlines

April 17, 2024 | americanbankingnews.com

Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update

March 29, 2024 | msn.com

3 Best Stocks to Buy Now, 3/29/2024, According to Top Analysts

April 19, 2024 | DTI (Ad)

Did you know you can now trade Bitcoin in your regular brokerage account?

You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history! That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords… Heck, you don’t even need a crypto wallet!

March 29, 2024 | markets.businessinsider.com

Aura Biosciences Inc: A Buy Rating on Strong Pipeline and Financial Health

March 28, 2024 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Molina Healthcare (MOH) and Aura Biosciences Inc (AURA)

March 28, 2024 | finance.yahoo.com

We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate

March 27, 2024 | investorplace.com

AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023

March 27, 2024 | benzinga.com

Recap: Aura Biosciences Q4 Earnings

April 19, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

March 27, 2024 | businesswire.com

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

March 13, 2024 | msn.com

National Assembly Counters Doctors Petition on SHIF

February 26, 2024 | businesswire.com

Aura Biosciences to Participate in Upcoming Investor Conferences

February 23, 2024 | benzinga.com

Aura Biosciences Stock (NASDAQ:AURA), Short Interest Report

January 7, 2024 | finance.yahoo.com

Owning 48% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA),

January 3, 2024 | markets.businessinsider.com

BTIG Reaffirms Their Buy Rating on Aura Biosciences Inc (AURA)

December 11, 2023 | finance.yahoo.com

Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a Bet

December 9, 2023 | benzinga.com

Aura Biosciences Stock (NASDAQ:AURA), Analyst Ratings, Price Targets, Predictions

December 7, 2023 | finance.yahoo.com

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

November 23, 2023 | finance.yahoo.com

Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to Trade

November 13, 2023 | markets.businessinsider.com

Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock

November 12, 2023 | finance.yahoo.com

David Johnson Bought 232% More Shares In Aura Biosciences

November 11, 2023 | msn.com

Insider Trading: Aura Biosciences Stock (NASDAQ:AURA) Bought by Insiders to the Tune of $16M

November 10, 2023 | msn.com

Aura Biosciences director David Johnson buys common shares worth ~$1.44M

November 10, 2023 | markets.businessinsider.com

Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock

November 8, 2023 | markets.businessinsider.com

Promising Phase 2 Trial Results and Market Potential Bolster Aura Biosciences’ Buy Rating

November 7, 2023 | msn.com

Why Aura Biosciences Stock Hit A New 52-Week Low Today

November 7, 2023 | markets.businessinsider.com

Aura Biosciences Prices Public Offering Of 11 Mln Shares Of At $9.00/shr

See More Headlines

Receive AURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/15/2023
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:AURA
CUSIP: N/A
CIK: 1501796
Web: www.aurabiosciences.com
Phone: 617-500-8864
Fax: N/A
Employees: 88
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.00
High Stock Price Target: $23.00
Low Stock Price Target: $19.00
Potential Upside/Downside: +192.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-76,410,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -42.20%
Return on Assets: -36.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.76
Quick Ratio: 18.76

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.58 per share
Price / Book: 1.57

Miscellaneous

Outstanding Shares: 49,500,000
Free Float: 46,583,000
Market Cap: $355.41 million
Optionable: Not Optionable
Beta: 0.36

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Elisabet de los Pinos Ph.D. (Age 51)
Founder, CEO, President & Director
Comp: $795.3k
Ms. Julie B. Feder (Age 54)
CFO, Secretary & Treasurer
Comp: $505.45k
Mr. Patrick Nealon
Senior Vice President of Clinical Development Operations
Dr. Bruce Brown M.D.
Senior VP & Therapeutic Area Head of Urologic Oncology
Dr. Anthony Daniels M.D.
Therapeutic Area Head of Ocular Oncology
Dr. Richard Mountfield Ph.D.
Senior Vice President of Regulatory Affairs & Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AURA Stock Analysis - Frequently Asked Questions

Should I buy or sell Aura Biosciences stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aura Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AURA shares.
View AURA analyst ratings or view top-rated stocks.
What is Aura Biosciences' stock price target for 2024?: 3 brokerages have issued twelve-month price targets for Aura Biosciences' shares. Their AURA share price targets range from $19.00 to $23.00. On average, they expect the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 197.0% from the stock's current price.
View analysts price targets for AURA or view top-rated stocks among Wall Street analysts.
How have AURA shares performed in 2024?: Aura Biosciences' stock was trading at $8.86 at the beginning of 2024. Since then, AURA stock has decreased by 20.2% and is now trading at $7.07.
View the best growth stocks for 2024 here.
Are investors shorting Aura Biosciences?: Aura Biosciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,450,000 shares, an increase of 9.4% from the March 15th total of 2,240,000 shares. Based on an average daily trading volume, of 179,700 shares, the short-interest ratio is presently 13.6 days. Currently, 6.2% of the company's stock are sold short.
View Aura Biosciences' Short Interest.
When is Aura Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our AURA earnings forecast.

How were Aura Biosciences' earnings last quarter?: Aura Biosciences, Inc. (NASDAQ:AURA) announced its quarterly earnings results on Wednesday, March, 15th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.06.
What ETFs hold Aura Biosciences' stock?: ETFs with the largest weight of Aura Biosciences (NASDAQ:AURA) stock in their portfolio include Loncar China Biopharma ETF (CHNA) and Range Cancer Therapeutics ETF (CNCR).AltShares Event-Driven ET (EVNT).
When did Aura Biosciences IPO?: Aura Biosciences (AURA) raised $81 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 5,400,000 shares at $14.00-$16.00 per share.
How do I buy shares of Aura Biosciences?: Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AURA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial